Search results for "pharmacogenetics."

showing 10 items of 79 documents

Pharmacogenomic and molecular docking studies on the cytotoxicity of the natural steroid wortmannin against multidrug-resistant tumor cells

2014

Wortmannin is a cytotoxic compound derived from the endophytic fungi Fusarium oxysporum, Penicillium wortmannii and Penicillium funiculosum that occurs in many plants, including medicinal herbs. The rationale to develop novel anticancer drugs is the frequent development of tumor resistance to the existing antineoplasic agents. Therefore, it is mandatory to analyze resistance mechanisms of novel drug candidates such as wortmannin as well to bring effective drugs into the clinic that have the potential to bypass or overcome resistance to established drugs and to substantially increase life span of cancer patients. In the present project, we found that P-glycoprotein-overexpressing tumor cells…

DrugATP Binding Cassette Transporter Subfamily BClass I Phosphatidylinositol 3-Kinasesmedia_common.quotation_subjectPharmaceutical ScienceAntineoplastic AgentsATP-binding cassette transporterDrug resistancePharmacologyBiologyWortmanninPhosphatidylinositol 3-Kinaseschemistry.chemical_compoundCell Line TumorDrug DiscoveryCluster AnalysisHumansCytotoxicityProtein kinase BPI3K/AKT/mTOR pathwayOligonucleotide Array Sequence Analysismedia_commonPharmacologyDrug Resistance MultipleAndrostadienesMolecular Docking SimulationMultiple drug resistanceComplementary and alternative medicinechemistryDrug Resistance NeoplasmPharmacogeneticsMolecular MedicineWortmanninSignal TransductionPhytomedicine
researchProduct

Pharmacogenomics in colorectal carcinomas: Future perspectives in personalized therapy

2005

The recent introduction of new drugs such as capecitabine, irinotecan, and oxaliplatinum has greatly improved the clinical outcome of patients with advanced/metastatic colorectal cancer. Nevertheless, some patients may suffer from the adverse drug reactions which will probably be the main cause of chemotherapy failure. The goal of pharmacogenomics is to find correlations between therapeutic responses to drugs and the genetic profiles of patients; the different responses to a particular drug are due, in fact, not only to the specific clinico-pathological features of the patient or to environmental factors, but also to the ethnic origins and the particular individual's genetic profile. Genes …

DrugPhysiologyColorectal cancermedia_common.quotation_subjectmedicine.medical_treatmentClinical BiochemistryPharmacologyBioinformaticsThymidylate synthaseCapecitabinemedicineDihydropyrimidine dehydrogenaseAnimalsHumansColorectal Neoplasms/geneticmedia_commonChemotherapyPolymorphism Geneticbiologybusiness.industryColorectal Neoplasms/drug therapyCell Biologymedicine.diseasePersonal Health ServicesIrinotecanPharmacogeneticsPharmacogenomicsbiology.proteinColorectal Neoplasmsbusinessmedicine.drugJournal of Cellular Physiology
researchProduct

Rash and multiorgan dysfunction following lamotrigine: could genetic be involved?

2015

We report the case of a 38-year-old woman treated with lamotrigine who experienced multi-organ dysfunction. The patient received the drug at the dose of 100 mg per day. One week later, the treatment was suspended because of an extensive body rash. Twenty-four hours later, the patient appeared drowsy and stuporous and was hospitalized. On the fifth day, the patient was admitted with a clinical picture of acute multi-organ failure in our Institute, where, she, despite the support of vital functions with vasoactive drugs, continuous hemofiltration and ventilation with oxygen, died. Serum lamotrigine concentration was measured 110 h after its last dose and the drug resulted to be still present …

DrugUGT1A4Genotypemedia_common.quotation_subjectMultiple Organ FailurePharmaceutical ScienceSNPPharmacyLamotrigineToxicologyLamotriginePolymorphism Single NucleotideVasoactiveRashmedicineHumansPharmacology (medical)GlucuronosyltransferaseUGT2B7media_commonPharmacologybusiness.industryTriazinesPharmacogeneticMultiorgan dysfunctionABCB1ExanthemaRashHLAMulti-organ dysfunctionAnesthesiaBreathingSettore BIO/14 - FarmacologiaAnticonvulsantsFemaleUGT1A4medicine.symptombusinessPharmacogeneticsAntiepileptic drugmedicine.drug
researchProduct

Pharmacogenetics and Forensic Toxicology: A New Step towards a Multidisciplinary Approach

2021

Pharmacogenetics analyzes the individual behavior of DNA genes after the administration of a drug. Pharmacogenetic research has been implemented in recent years thanks to the improvement in genome sequencing techniques and molecular genetics. In addition to medical purposes, pharmacogenetics can constitute an important tool for clarifying the interpretation of toxicological data in post-mortem examinations, sometimes crucial for determining the cause and modality of death. The purpose of this systematic literature review is not only to raise awareness among the forensic community concerning pharmacogenetics, but also to provide a workflow for forensic toxicologists to follow in cases of unk…

Drugmedicine.medical_specialtyHealth Toxicology and Mutagenesismedia_common.quotation_subjectdrug-related deathMedical malpracticeTP1-1185ToxicologyPharmacogenetic StudySudden deathMolecular autopsySettore MED/43 - Medicina LegaleSettore BIO/10 - BiochimicamedicineDrug-related deathforensic toxicologyIntensive care medicinemedia_commonpharmacogeneticsMultidisciplinary approachChemical Health and Safetybusiness.industryChemical technologyForensic toxicologyForensic toxicologySystematic reviewPharmacogeneticsmolecular autopsypharmacogeneticmultidisciplinary approachSettore BIO/14 - FarmacologiaSystematic ReviewbusinessPharmacogeneticsMethadonemedicine.drug
researchProduct

Colorectal cancer: pharmacogenetics support for the correct drug prescription

2019

Pharmacogenetics (PGx) in clinical practice is a tool that the clinician can use to guide, in a personalized way, the most suitable treatment that will be administered to the patient. The objective of this review is to summarize in a practical and accessible rational way, the advances that currently exist for the application of PGx in colorectal cancer chemotherapy management through the study of the patients’ germline polymorphisms. To define the polymorphisms that can be applied, we rely on three fundamental cornerstones: the recommendations of drug regulatory agencies; the implementation guidelines prepared by expert consortia in PGx and information from clinical annotations (the drug/p…

Drugmedicine.medical_specialtyPharmGKBColorectal cancermedia_common.quotation_subjectAntineoplastic AgentsDrug PrescriptionsPolymorphism Single NucleotideGeneticsmedicineAnimalsHumansPrecision MedicineMedical prescriptionIntensive care medicinemedia_commonPharmacologybusiness.industryfood and beveragesEvidence-based medicinemedicine.diseaseClinical PracticePharmacogeneticsMolecular MedicineColorectal NeoplasmsbusinessPharmacogeneticsPharmacogenomics
researchProduct

Adverse drug reaction and organ damage: the liver

2016

Drug-induced liver injury (DILI) is among the most challenging acute or chronic liver conditions to be handled by physicians. Despite its low incidence in the general population, DILI is a frequent cause of acute liver failure. As such, the possibility of DILI should be considered in all patients who present with acute liver damage, independent of any known pre-existing liver disease. DILI can be classified as intrinsic/dose-dependent (e.g., acetaminophen toxicity) or idiosyncratic/dose-independent, with the latter form being relatively uncommon. Amoxicillin-clavulanate is the antimicrobial that is most frequently associated with idiosyncratic DILI. Large, ongoing, prospective studies in we…

Drugmedicine.medical_specialtySettore MED/09 - Medicina InternaClinical presentationEpidemiologymedia_common.quotation_subjectPopulation03 medical and health sciencesLiver disease0302 clinical medicineRisk FactorsEpidemiologyInternal MedicinemedicineHumansRisk factorIntensive care medicineeducationmedia_commonLiver injuryeducation.field_of_studybusiness.industryIncidenceAnti-Inflammatory Agents Non-SteroidalBiomarkers; Clinical presentation; Diagnosis; Drug induced liver injury; Epidemiology; Risk factorBiomarkermedicine.diseaseDrug development030220 oncology & carcinogenesisDietary Supplements030211 gastroenterology & hepatologyPlant PreparationsDrug induced liver injuryRisk factorChemical and Drug Induced Liver InjuryHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPharmacogeneticsDiagnosi
researchProduct

Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidep…

2021

Contains fulltext : 238693.pdf (Publisher’s version ) (Open Access) Objectives: More than 40 drugs are available to treat affective disorders. Individual selection of the optimal drug and dose is required to attain the highest possible efficacy and acceptable tolerability for every patient.Methods: This review, which includes more than 500 articles selected by 30 experts, combines relevant knowledge on studies investigating the pharmacokinetics, pharmacodynamics and pharmacogenetics of 33 antidepressant drugs and of 4 drugs approved for augmentation in cases of insufficient response to antidepressant monotherapy. Such studies typically measure drug concentrations in blood (i.e. therapeutic …

Drugmedicine.medical_specialtyprecision medicinetherapeutic drug monitoringmedia_common.quotation_subjectStress-related disorders Donders Center for Medical Neuroscience [Radboudumc 13]brain imagingNeuroimagingPsykiatri03 medical and health sciences0302 clinical medicinePharmacotherapyNeuroimagingmedicineHumansIntensive care medicineBiological Psychiatrypharmacogeneticsmedia_commonPsychiatrymedicine.diagnostic_testbusiness.industryAntidepressantsPrecision medicineAntidepressive Agents030227 psychiatryPsychiatry and Mental healthTherapeutic drug monitoringPharmacogeneticsAntidepressants; brain imaging; pharmacogenetics; precision medicine; therapeutic drug monitoring; Antidepressive Agents; Drug Monitoring; Humans; Neuroimaging; Pharmacogenetics; PsychiatryAntidepressants; brain imaging; precision medicine; pharmacogenetics; therapeutic drug monitoringDrug MonitoringbusinessPharmacogeneticsWorld Journal of Biological Psychiatry
researchProduct

Value of genetic and epigenetic testing as biomarkers of response to antidepressant treatment

2013

Major depressive disorder (MDD) is one of the most prevalent and disabling psychiatric disorders worldwide and therefore an important public health priority. The selection process of antidepressant treatment is primarily guided by trial and error, and the outcomes with current antidepressant strategies are disappointing. The biological background of the disease is heterogeneous with presumably multiple biological systems involved. With the aim to individualize antidepressant treatment, multiple candidate gene and a few genome-wide association studies have been performed, but so far with very limited success. To address the dynamic changes of depressive symptoms and their response to treatme…

EpigenomicsDepressive Disorder Majormedicine.medical_specialtyCandidate genemedicine.diagnostic_testDiseasemedicine.diseaseAntidepressive AgentsPsychiatry and Mental healthPharmacogeneticsmedicineHumansBiomarker (medicine)Major depressive disorderAntidepressantGenetic TestingPsychologyPsychiatryBiomarkersPharmacogeneticsEpigenomicsGenetic testingInternational Review of Psychiatry
researchProduct

Genetics of Inflammation in Age-Related Atherosclerosis: Its Relevance to Pharmacogenomics

2007

In response to tissue injury elicited by trauma or infection, the inflammatory response, as a complex network of molecular and cellular interactions, sets an answer directed to facilitate a return to physiological homeostasis and tissue repair. The role of the genetic background and the subsequent predisposition toward the extent of the inflammatory response is determined by gene variability encoding endogenous mediators involved in the inflammatory pathway. Due to its clinical relevance, the genetics of inflammation in aging will be studied using an inflammatory disease like atherosclerosis as an example. Several studies have reported a significant difference in distribution, between patie…

GenotypeEndogenyInflammationDiseaseBiologyInfectionsGeneral Biochemistry Genetics and Molecular BiologyProinflammatory cytokineatherosclerosiHistory and Philosophy of SciencemedicineHumansGenetic Predisposition to DiseaseClinical significanceAlleleGeneAllelesAgedpharmacogenomicsSettore MED/04 - Patologia GeneraleGeneticsPolymorphism GeneticGeneral NeuroscienceToll-Like ReceptorsagingGenetic VariationAtherosclerosisPhenotypePharmacogeneticsinflammationMultigene FamilyPharmacogenomicsImmunologygeneticmedicine.symptomAnnals of the New York Academy of Sciences
researchProduct

Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients

2013

The introduction of tacrolimus in clinical practice has improved patient survival after organ transplant. However, despite the long use of tacrolimus in clinical practice, the best way to use this agent is still a matter of intense debate. The start of the genomic era has generated new research areas, such as pharmacogenetics, which studies the variability of drug response in relation to the genetic factors involved in the processes responsible for the pharmacokinetics and/or the action mechanism of a drug in the body. This variability seems to be correlated with the presence of genetic polymorphisms. Genotyping is an attractive option especially for the initiation of the dosing of tacrolim…

Graft Rejectionmedicine.medical_specialtyCYP3A5ATP Binding Cassette Transporter Subfamily BCYP3A4Genotypemedicine.medical_treatmentPharmacologyLiver transplantationBioinformaticsOrgan transplantationTacrolimusCalcineurin inhibitorMedicineCytochrome P-450 CYP3AHumansDrug Dosage CalculationsDosingATP Binding Cassette Transporter Subfamily B Member 1Topic HighlightKidney transplantLiver transplantKidney transplantationBiotransformationPolymorphism Geneticbusiness.industryPharmacogeneticGraft SurvivalGastroenterologyABCB1General Medicinemedicine.diseaseKidney TransplantationTacrolimusLiver TransplantationSingle nucleotide polymorphismTransplantationsurgical procedures operativePhenotypeTreatment OutcomePharmacogeneticsTacrolimuSettore BIO/14 - FarmacologiaPersonalized medicinebusinessPharmacogeneticsImmunosuppressive Agents
researchProduct